for prevention of photoxicity in adult patients with erythropoietic protoporphyria (EPP). Scenesse is to be administered under a Post-Authorisation Safety Study (PASS) protocol in line with the approved European Medicines Agency Risk Management Plan.

Medicine details

Medicine name:
afamelanotide (Scenesse)
Pharmaceutical company
Clinuvel (UK) Ltd
BNF chapter
Nutrition and blood
Submission type
Full submission
Advice due date:
SMC meeting date:
04 July 2017
Patient group submission deadline:
01 May 2017